<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00086944</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02600</org_study_id>
    <secondary_id>12975A</secondary_id>
    <secondary_id>N01CM62201</secondary_id>
    <secondary_id>CDR0000371904</secondary_id>
    <nct_id>NCT00086944</nct_id>
  </id_info>
  <brief_title>Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase I/II Study of G3139 (Genasense) in Combination With RICE Chemotherapy in Relapsed B-Cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I/II trial is studying the side effects and best dose of oblimersen when given&#xD;
      together with rituximab and combination chemotherapy and to see how well they work in&#xD;
      treating patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Monoclonal&#xD;
      antibodies such as rituximab can locate cancer cells and either kill them or deliver&#xD;
      cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy,&#xD;
      such as ifosfamide, carboplatin, and etoposide, work in different ways to stop cancer cells&#xD;
      from dividing so they stop growing or die. Oblimersen may increase the effectiveness of&#xD;
      chemotherapy by making cancer cells more sensitive to the drugs&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of oblimersen when given in combination with&#xD;
      rituximab, ifosfamide, carboplatin, and etoposide in patients with relapsed or refractory&#xD;
      aggressive B-cell non-Hodgkin's lymphoma.&#xD;
&#xD;
      II. Determine the safety and toxicity of this regimen in these patients. III. Determine the&#xD;
      complete and partial response rate in patients treated with this regimen.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the duration of response, overall survival, and time to progression in patients&#xD;
      treated with this regimen.&#xD;
&#xD;
      II. Determine the effect of this regimen on hematopoietic stem cell kinetics and yield from&#xD;
      these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I, dose-escalation study of oblimersen followed by a&#xD;
      phase II study.&#xD;
&#xD;
      Phase I: Patients receive GRICE comprising oblimersen IV continuously on days 1-5, rituximab&#xD;
      IV, ifosfamide IV continuously over 24 hours, and carboplatin IV over 1 hour on day 4, and&#xD;
      etoposide IV over 30 minutes once daily on days 4-6. Treatment repeats every 14 days for 3&#xD;
      courses. Patients also receive filgrastim (G-CSF) subcutaneously (SC) once daily beginning on&#xD;
      day 7 and continuing until blood counts recover OR one dose of pegfilgrastim SC on day 7 of&#xD;
      courses 1 and 2. For course 3, all patients receive G-CSF SC twice daily beginning on day 7&#xD;
      and continuing until stem cell collection is complete. Patients with responding disease who&#xD;
      are not eligible for autologous SCT may receive up to 8 total courses of GRICE or 2&#xD;
      additional courses beyond maximal response. Patients with responding disease to GRICE who are&#xD;
      eligible for autologous SCT are removed from the study and undergo autologous SCT off study.&#xD;
      Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Phase II: Patients receive oblimersen at the MTD determined in phase I and rituximab,&#xD;
      ifosfamide, carboplatin, and etoposide followed by G-CSF or pegfilgrastim as in phase I. In&#xD;
      both phases, treatment continues in the absence of disease progression, unacceptable&#xD;
      toxicity, or the patient becomes a candidate for autologous SCT. Patients are followed for&#xD;
      survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity graded using the NCI CTCAE version 3.0</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete and partial response rate according to the International Workshop Criteria</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From the time measurement criteria are met for CR/CRu/PR until the first date that PD is objectively documented, assessed up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the first day of therapy to the date of death, assessed up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>From the first day of treatment until the date PD or death is first reported, assessed up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (genase, combination chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>oblimersen sodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (genase, combination chemotherapy)</arm_group_label>
    <other_name>augmerosen</other_name>
    <other_name>G3139</other_name>
    <other_name>G3139 bcl-2 antisense oligodeoxynucleotide</other_name>
    <other_name>Genasense</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (genase, combination chemotherapy)</arm_group_label>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 monoclonal antibody</other_name>
    <other_name>Mabthera</other_name>
    <other_name>MOAB IDEC-C2B8</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (genase, combination chemotherapy)</arm_group_label>
    <other_name>Cyfos</other_name>
    <other_name>Holoxan</other_name>
    <other_name>IFF</other_name>
    <other_name>IFX</other_name>
    <other_name>IPP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (genase, combination chemotherapy)</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (genase, combination chemotherapy)</arm_group_label>
    <other_name>EPEG</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (genase, combination chemotherapy)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (genase, combination chemotherapy)</arm_group_label>
    <other_name>Filgrastim SD-01</other_name>
    <other_name>GCSF-SD01</other_name>
    <other_name>Neulasta</other_name>
    <other_name>SD-01 sustained duration G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (genase, combination chemotherapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed aggressive B-cell non-Hodgkin's lymphoma&#xD;
&#xD;
               -  Any 1 one of the following histological subtypes for phase I:&#xD;
&#xD;
                    -  Grade 3 follicular center lymphoma&#xD;
&#xD;
                    -  Diffuse large B-cell lymphoma&#xD;
&#xD;
                    -  Transformed follicular lymphoma&#xD;
&#xD;
                    -  Mantle cell lymphoma&#xD;
&#xD;
                    -  Primary mediastinal B-cell lymphoma&#xD;
&#xD;
               -  Any 1 of the following histological subtypes for phase II:&#xD;
&#xD;
                    -  Diffuse large B-cell lymphoma&#xD;
&#xD;
                    -  Transformed follicular lymphoma&#xD;
&#xD;
                    -  Primary mediastinal B-cell lymphoma&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 bidimensionally measurable lesion ≥ 10 mm in longest diameter by CT&#xD;
                  scan, MRI, x-ray, or clinical exam&#xD;
&#xD;
          -  Relapsed disease after 1, and only 1, prior anthracycline-based chemotherapy regimen&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3*&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3*&#xD;
&#xD;
          -  Bilirubin normal**&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  PT and PTT normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to oblimersen or other study drugs&#xD;
&#xD;
          -  No currently active second malignancy except nonmelanoma skin cancer or carcinoma in&#xD;
             situ of the cervix&#xD;
&#xD;
               -  Must have completed any prior therapy for a second malignancy and is considered&#xD;
                  to be at &lt; 30% risk of relapse&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  Prior rituximab allowed&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for nitrosoureas or&#xD;
             mitomycin) and recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent therapeutic radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior surgery&#xD;
&#xD;
          -  No prior oblimersen or other antisense oligonucleotide therapy&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonali Smith</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Oblimersen</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

